Anxious-depressive Pathology in the Structure of Adaptation Disorders (Clinics, Diagnosis, Therapy)
Authors: Maruta Nataliia , Fedchenko Viktoriia 
Published: July 2021

The objective: evaluation of the effectiveness of the drug Giacintia (escitalopram) – coated tablets, 10 mg in the treatment of patients with anxiety and depressive symptoms in the structure of adaptation disorders.
Materials and methods. The study involved 38 patients with adaptive disorders, mixed anxiety-depressive response to ICD-10 (F 43.22). All patients received Giacintia at a dose of 10 mg per day, due to the sufficient therapeutic effect of this dosage. A comprehensive approach was used, which included methods: clinical and psychopathological; psychodiagnostic, based on the scale «Questionnaire of severity of psychopathological symptoms» (Symptom Check List-90-Revised – SCL-90-R), hospital scale of anxiety and depression (HADS) and the scale of social adaptation Sheehan (SDS); methods of mathematical statistics.
Results. Peculiarities of patients’ clinical condition and its dynamics were assessed before treatment (day 1), during therapy (day 14), and after treatment (day 90). As a result of Giacintia therapy, a significant improvement in the mental state of patients was found. When studying the regression of psychopathological symptoms, the positive dynamics of depressive disorders in this category of persons was observed by the end of the second week of therapy, and on the part of anxious – up to 21 days of therapy. Examination of patients at the end of the 90-day course of Giacintia treatment revealed a significant reduction in all previously recorded symptoms of anxiety and depression compared with baseline (p<0.05). On the SCL-90-R scale, on day 14 of therapy, patients showed a significant decrease in obsessive-compulsive symptoms, signs of paranoia (suspicion), hostility (feelings of anger), depressive symptoms, and phobic anxiety. Subsequently, there was a significant decrease in existing psychopathological symptoms and a probable decrease in all scales on day 90 of therapy with the studied antidepressant (t≥2,3477). At the time of the final assessment, the indicator on the scale of depression decreased to 0,52 points, and on the scale of anxiety – to 0,56 points, which indicates a reduction in clinically = pronounced anxiety and depressive symptoms. According to the HADS scale at the initial assessment of clinical and psychopathological manifestations of anxiety and depression, clinically expressed symptoms of anxiety were registered in 71,05 % of individuals (mean score – 15,00±2,39 points), subclinical – in 28,95 % of individuals (mean score – 8,82±0,75 points). At the same time, clinically pronounced symptoms of depression were registered in 81,58 % of individuals (mean score – 15,23±2,33 points), subclinical – in 18,42 % of individuals (mean score – 8,43±0,53 points). A significant decrease in the percentage of clinically pronounced manifestations of depressive symptoms was registered on day 14 of therapy (57,89 % of individuals, p<0,05). At the time of the final HADS assessment, clinically significant symptoms of anxiety and depression were completely reduced in the study group and were represented only by subclinical manifestations in 13,16 % of patients and 11,43 % of patients, respectively.
Conclusions. The results of the study showed high efficacy and good tolerability of the drug Giacintia in the treatment of anxiety and depressive symptoms in the structure of adaptation disorders. Giacintia has not only a balanced pronounced thymoanaleptic effect, but also provides increased professional, social and family activity and improves the quality of life of patients in general. Especially important is the good tolerability of the drug confirmed by the study, the unstable transient nature of adverse events, their insignificant severity, which is a significant advantage in the formation of patients’ commitment to treatment and achieving a deeper and more lasting therapeutic effect. Thus, the use of Giacintia can successfully overcome adaptation disorders and prevent their transformation into chronic conditions.